FDA Sodium Targets Show Little Impact

In 2021 the U.S. Food and Drug Administration (FDA) released Phase I voluntary sodium‑reduction targets, urging packaged‑food manufacturers to cut sodium levels in their products by 2024. The guidance set specific reduction goals for a range of food categories, aiming to improve public health by lowering sodium intake across the population.

A recent study examined the sodium content of newly launched products before and after the FDA’s guidance was issued. By comparing product labels and ingredient lists, the researchers found only marginal changes in sodium levels, suggesting that the voluntary targets had limited influence on manufacturers’ formulation decisions. The analysis highlighted that many new products continued to meet or exceed the sodium levels seen in earlier releases, raising questions about the effectiveness of non‑mandatory industry initiatives.

The findings imply that voluntary measures alone may not be sufficient to drive meaningful sodium reductions in packaged foods. Policymakers and public‑health advocates may need to consider stronger regulatory tools or incentives to achieve the sodium‑reduction goals set by the FDA.